01 mayo 2016

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. Comparison of sirolimus eluting stent with bioresorbable polymer to everolimus eluting stent with permanent polymer in bifurcation lesions: Results from CENTURY II trial

K Orvin MD1, D. Carrie MD2, G. Richardt MD3, W. Desmet MD4, A. Assali MD1, G. Werner MD5, Y. Ikari MD6, K. Fujii MD7, J. Goicolea MD8, V. Dangoisse MD9, A. Manari MD10, S. Saito MD11, W. Wijns MD12 andR. Kornowski MD1,*

Objective: To demonstrate the safety and efficacy of a new sirolimus eluting stent with bioresorbable polymer, Ultimaster, (BP-SES) compared with everolimus-eluting, permanent polymer, Xience stent (PP-EES) in bifurcation lesions with respect to the freedom from Target Lesion Failure at 1-year.

01 mayo 2016

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. Management of drug eluting stent in-stent restenosis: A systematic review and meta-analysis

Sachin S. Goel MD1, Rama Dilip Gajulapalli MD2, Ganesh Athappan MD3, Femi Philip MD4, Supriya Gupta MD2, E. Murat Tuzcu MD2, Stephen G. Ellis MD2, Gregory Mishkel MD1 andSamir R. Kapadia MD2,*

Background: The optimal management for coronary drug eluting stent in-stent restenosis (DES ISR) is unclear. We performed a meta-analysis of observational and randomized studies to compare the outcomes of management of DES ISR using DES, drug eluting balloon (DEB), or balloon angioplasty (BA).

01 mayo 2016

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. Microvascular dysfunction in the immediate aftermath of chronic total coronary occlusion recanalization

Andrew Ladwiniec MA, MBBS, MRCP*, Michael S. Cunnington BMEDSCI, MD, MRCP, Jennifer Rossington BSC, MRCP, Simon Thackray MBBS, MD, MRCP, Farquad Alamgir MD, MRCP andAngela Hoye MBCHB, PhD, FRCP

Objectives: The aim of this study was to compare microvascular resistance under both baseline and hyperemic conditions immediately after percutaneous coronary intervention (PCI) of a chronic total occlusion (CTO) with an unobstructed reference vessel in the same patient

01 mayo 2016

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. Association of periprocedural myocardial infarction with long-term survival in patients treated with coronary revascularization therapy of chronic total occlusion

Woo Jin Jang MD1,†, Jeong Hoon Yang MD, PhD2, Seung-Hyuk Choi MD, PhD2,†,*, Young Bin Song MD, PhD2, Joo-Yong Hahn MD, PhD2, Wook Sung Kim MD, PhD2, Young Tak Lee MD, PhD2, Bum-Sung Kim MD3 andHyeon-Cheol Gwon MD, PhD

Objective: To evaluate the impact of periprocedural myocardial infarction (PMI) on long-term survival after coronary revascularization in patients with chronic total occlusion (CTO).

01 marzo 2016

CATHETERIZATION & CARDIOVASCULAR INTERVENTIONS. When is rotational angiography superior to conventional single-plane angiography for planning coronary angioplasty?

Paul D. Morris BMEDSCI, MBCHB, MRCP1,2,3,*, Jane Taylor BMEDSCI, MBCHB1, Sara Boutong BMEDSCI, MBCHB1, Sarah Brett MD, FRCP2, Amal Louis MD, MRCP2, James Heppenstall DCR(R), PGCERT2, Allison C. Morton PhD, FRCP2 andJulian P. Gunn MD, MRCP1,2,3

Objectives: To investigate the value of rotational coronary angiography (RoCA) in the context of percutaneous coronary intervention (PCI) planning.

01 abril 2016

AMERICAN HEART JOURNAL. Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial

Giuseppe Gargiulo, MD, Francesco Costa, MD, Sara Ariotti, MD, Simone Biscaglia, MD, Gianluca Campo, MD, Giovanni Esposito, MD, PhD, Sergio Leonardi, MD, Pascal Vranckx, MD, PhD, Stephan Windecker, MD, Marco Valgimigli, MD, PhD

Background: Proton pump inhibitors (PPIs) are frequently prescribed in combination with clopidogrel, but conflicting data exist as to whether PPIs diminish the efficacy of clopidogrel. We assessed the association between PPI use and clinical outcomes for patients treated with percutaneous coronary intervention (PCI) and dual-antiplatelet therapy (DAPT) with clopidogrel plus aspirin.

01 mayo 2016

AMERICAN HEART JOURNAL. Ten-year clinical outcomes after sirolimus-eluting stent implantation: Impact of an in-stent restenosis target lesion

Katsuya Miura, MD, Kazushige Kadota, MD, PhD, Seiji Habara, MD, Hiroshi Miyawaki, MD, Takenobu Shimada, MD, Masanobu Ohya, MD, Hidewo Amano, MD, Yu Izawa, MD, Yusuke Hyodo, MD, Suguru Otsuru, MD, Daiji Hasegawa, MD, Takeshi Tada, MD, PhD, Hiroyuki Tanaka, MD, Yasushi Fuku, MD, Tsuyoshi Goto, MD, Kazuaki Mitsudo, MD

Background: Little is known about the long-term outcomes after first-generation sirolimus-eluting stent (SES) implantation. We aimed to investigate the clinical outcomes up to 10 years after SES implantation.

01 marzo 2016

AMERICAN HEART JOURNAL. Rationale and design of POPular-TAVI: antiPlatelet therapy fOr Patients undergoing Transcatheter Aortic Valve Implantation

Vincent Johan Nijenhuis, MD, Naoual Bennaghmouch, MD, Mariella Hassell, MD, Jan Baan Jr., MD, PhD, Jan Peter van Kuijk, MD, PhD, Pierfrancesco Agostoni, MD, PhD, Arnoud van ‘t Hof, MD, PhD, Peter C. Kievit, MD, PhD, Leo Veenstra, MD, Pim van der Harst, MD, PhD, Ad F.M. van den Heuvel, MD, PhD, Peter den Heijer, MD, PhD, Johannes C. Kelder, MD, PhD, Vera H. Deneer, PharmD, PhD, Frank van der Kley, MD, Francesco Onorati, MD, PhD, Jean Philippe Collet, MD, PhD, Francesco Maisano, MD, PhD, Azeem Latib, MD, PhD, Kurt Huber, MD, PhD, Pieter R. Stella, MD, PhD, Jurrien M. ten Berg, MD, PhD

Background: Despite improving experience and techniques, ischemic and bleeding complications after transcatheter aortic valve implantation (TAVI) remain prevalent and impair survival. Current guidelines recommend the temporary addition of clopidogrel in the initial period after TAVI to prevent thromboembolic events. However, explorative studies suggest that this is associated with a higher rate of major bleeding without a decrease in thromboembolic complications.

01 marzo 2016

AMERICAN HEART JOURNAL. Renal failure in patients with ST-segment elevation acute myocardial infarction treated with primary percutaneous coronary intervention: Predictors, clinical and angiographic features, and outcomes

John P. Vavalle, MD, MHS, Sean van Diepen, MD, Robert M. Clare, MS, Judith S. Hochman, MD, W. Douglas Weaver, MD, Rajendra H. Mehta, MD, Karen S. Pieper, MS, Manesh R. Patel, MD, Uptal D. Patel, MD, Paul W. Armstrong, MD, Christopher B. Granger, MD, Renato D. Lopes, MD, PhD

Background: Among patients presenting with ST-segment elevation myocardial infarction (STEMI) for primary percutaneous coronary intervention (PCI), the associations between clinical outcomes and both baseline renal function and the development of acute kidney injury (AKI) have not been reported in a trial population with unselected baseline renal function.

01 marzo 2016

AMERICAN HEART JOURNAL. RenalGuard system in high-risk patients for contrast-induced acute kidney injury

Carlo Briguori, MD, PhD, Gabriella Visconti, MD, Michael Donahue, MD, Francesca De Micco, PhD, Amelia Focaccio, MD, Bruno Golia, MD, Giuseppe Signoriello, PhD, Carmine Ciardiello, PhD, Elvira Donnarumma, PhD, Gerolama Condorelli, MD, PhD

Background: High urine flow rate (UFR) has been suggested as a target for effective prevention of contrast-induced acute kidney injury (CI-AKI). The RenalGuard therapy (saline infusion plus furosemide controlled by the RenalGuard system) facilitates the achievement of this target.

01 marzo 2016

AMERICAN HEART JOURNAL. Optimal medical therapy with or without percutaneous coronary intervention in women with stable coronary disease: A pre-specified subset analysis of the Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluation (COURAGE) trial

Subroto Acharjee, MD, Koon K. Teo, MB, BCH, PHD, Alice K. Jacobs, MD, Pamela M. Hartigan, PHD, Kulpreet Barn, MD, Gilbert Gosselin, MD, Jean-Francois Tanguay, MD, David J. Maron, MD, William J. Kostuk, MD, Bernard R. Chaitman, MD, G.B. John Mancini, MD, John A. Spertus, MD, MPH, Marcin R. Dada, MD, Eric R. Bates, MD, David C. Booth, MD, William S. Weintraub, MD, Robert A. O’Rourke, MDr, William E. Boden, MD

Objectives: To determine whether sex-based differences exist in clinical effectiveness of percutaneous coronary intervention (PCI) when added to optimal medical therapy (OMT) in patients with stable coronary artery disease.

01 marzo 2016

AMERICAN HEART JOURNAL. Clinical profiles and correlates of mortality in nonagenarians with severe aortic stenosis undergoing transcatheter aortic valve replacement

Ricardo O. Escárcega, MD, Nevin C. Baker, DO, Michael J. Lipinski, MD, PhD, Edward Koifman, MD, Sarkis Kiramijyan, MD, Marco A. Magalhaes, MD, Jiaxiang Gai, MSPH, Rebecca Torguson, MPH, Lowell F. Satler, MD, Augusto D. Pichard, MD, Ron Waksman, MD

Background: Transcatheter aortic valve replacement (TAVR) is the current standard for nonoperable and high-risk surgical patients with aortic stenosis, including those of advanced age. However, the clinical profiles, procedural characteristics, and outcomes of nonagenarians undergoing TAVR have not been thoroughly reported.

01 marzo 2016

AMERICAN HEART JOURNAL. Incidence and characteristics of inappropriate and false-positive cardiac catheterization laboratory activations in a regional primary percutaneous coronary intervention program

Jonathan Lu, MD, Akshay Bagai, MD, MHS, Chris Buller, MD, Asim Cheema, MD, PhD, John Graham, MBChB, Michael Kutryk, MD, PhD, Jo-Ann Christie, RN, Neil Fam, MD, MSc

Background: The implementation of regional primary percutaneous coronary intervention (PCI) programs has been critical in achieving timely intervention in patients with ST-segment elevation myocardial infarction (STEMI). However, 1 consequence has been inappropriate and false-positive cardiac catheterization laboratory (CCL) activations where either angiography is cancelled or no culprit lesion is found, respectively.

01 marzo 2016

AMERICAN HEART JOURNAL. Addition of cilostazol to aspirin therapy for secondary prevention of cardiovascular and cerebrovascular disease in patients undergoing percutaneous coronary intervention: A randomized, open-label trial

Hiroshi Ueda, MD, Atsumichi Kido, MD, Seiji Matsuhisa, MD, PhD, Koichiro Asawa, MD, PhD, Naohiro Yoshida, MD, Mitsuru Tsujimoto, MD, Yasushi Sasaki, MD, Yukiko Kuga, MD, PhD, Masaki Yamasaki, MD, Kazuya Ueda, MD, Shoichi Shinohara, MD, Yasunori Nishida, MD

Background: Patients with established coronary artery disease are at increased risk for future ischemic events and require secondary prevention for systemic vascular disease. We performed a randomized clinical trial to evaluate the impact of cilostazol on cardiovascular and cerebrovascular disease in patients undergoing percutaneous coronary intervention.

01 marzo 2016

CANADIAN JOURNAL OF CARDIOLOGY. Left Atrial Appendage Closure for Atrial Fibrillation Is Safe and Effective After Intracranial or Intraocular Hemorrhage

Peter Fahmy, MBChB, Ryan Spencer, MD, Michael Tsang, MD, Peter Gooderham, MD, Jacqueline Saw, MD

Background: Atrial fibrillation (AF) affects 1%-2% of the general population and 13% of individuals older than 80 years of age. Anticoagulation has been the mainstay therapy to reduce stroke risk. Patients with previous intracranial hemorrhage (ICH) or intraocular hemorrhage (IOH) are at increased risk of recurrence if anticoagulation is continued or initiated. Left atrial appendage (LAA) closure may obviate the need for long-term anticoagulation in these patients.